Snap-on Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Snap-on Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $5.16B | Feb 12, 2026 |
| FY2025 | Dec 28, 2024 | $5.11B | Feb 12, 2026 |
| FY2025 | Dec 30, 2023 | $5.11B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $4.84B | Feb 13, 2025 |
| FY2023 | Jan 1, 2022 | $4.60B | Feb 16, 2024 |
| FY2022 | Jan 2, 2021 | $3.94B | Feb 9, 2023 |
| FY2021 | Dec 28, 2019 | $4.07B | Feb 11, 2022 |
| FY2020 | Dec 29, 2018 | $4.07B | Feb 11, 2021 |
| FY2019 | Dec 30, 2017 | $4.00B | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $3.71B | Feb 14, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $4.71B | Feb 12, 2026 |
| FY2025 | Dec 28, 2024 | $4.68B | Feb 12, 2026 |
| FY2025 | Dec 30, 2023 | $4.70B | Feb 12, 2026 |
| FY2023 | Dec 31, 2022 | $4.47B | Feb 16, 2024 |
| FY2022 | Jan 1, 2022 | $4.23B | Feb 9, 2023 |
| FY2021 | Jan 2, 2021 | $3.57B | Feb 11, 2022 |
| FY2020 | Dec 28, 2019 | $3.71B | Feb 11, 2021 |
| FY2019 | Dec 29, 2018 | $3.72B | Feb 13, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 30, 2017 | $974.60M | Feb 15, 2018 |
| FY2017 | Sep 30, 2017 | $903.80M | Feb 15, 2018 |
| FY2017 | Jul 1, 2017 | $921.40M | Feb 15, 2018 |
| FY2017 | Apr 1, 2017 | $887.10M | Feb 15, 2018 |
| FY2016 | Dec 31, 2016 | $889.80M | Feb 9, 2017 |
| FY2016 | Oct 1, 2016 | $834.10M | Feb 9, 2017 |
| FY2016 | Jul 2, 2016 | $872.30M | Feb 9, 2017 |
| FY2016 | Apr 2, 2016 | $834.20M | Feb 9, 2017 |
| FY2015 | Jan 2, 2016 | $851.70M | Feb 11, 2016 |
| FY2015 | Oct 3, 2015 | $821.50M | Feb 11, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 30, 2017 | $465.30M | Feb 15, 2018 |
| FY2017 | Sep 30, 2017 | $448.60M | Feb 15, 2018 |
| FY2017 | Jul 1, 2017 | $463.00M | Feb 15, 2018 |
| FY2017 | Apr 1, 2017 | $448.00M | Feb 15, 2018 |
| FY2016 | Dec 31, 2016 | $443.90M | Feb 9, 2017 |
| FY2016 | Oct 1, 2016 | $419.10M | Feb 9, 2017 |
| FY2016 | Jul 2, 2016 | $431.30M | Feb 9, 2017 |
| FY2016 | Apr 2, 2016 | $415.30M | Feb 9, 2017 |
| FY2015 | Jan 2, 2016 | $412.30M | Feb 11, 2016 |
| FY2015 | Oct 3, 2015 | $406.90M | Feb 11, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $1.02B | Feb 12, 2026 |
| FY2025 | Dec 28, 2024 | $1.04B | Feb 12, 2026 |
| FY2025 | Dec 30, 2023 | $1.01B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $911.70M | Feb 13, 2025 |
| FY2023 | Jan 1, 2022 | $820.50M | Feb 16, 2024 |
| FY2020 | Jan 2, 2021 | $208.90M | Feb 11, 2021 |
| FY2020 | Sep 26, 2020 | $179.70M | Feb 11, 2021 |
| FY2020 | Jun 27, 2020 | $101.20M | Feb 11, 2021 |
| FY2020 | Mar 28, 2020 | $137.20M | Feb 11, 2021 |
| FY2020 | Dec 28, 2019 | $170.60M | Feb 11, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $1.33B | Feb 12, 2026 |
| FY2025 | Dec 28, 2024 | $1.35B | Feb 12, 2026 |
| FY2025 | Dec 30, 2023 | $1.31B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.21B | Feb 13, 2025 |
| FY2023 | Jan 1, 2022 | $1.12B | Feb 16, 2024 |
| FY2022 | Jan 2, 2021 | $880.50M | Feb 9, 2023 |
| FY2021 | Dec 28, 2019 | $962.30M | Feb 11, 2022 |
| FY2020 | Dec 29, 2018 | $956.10M | Feb 11, 2021 |
| FY2019 | Dec 30, 2017 | $882.10M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $861.10M | Feb 14, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $72.40M | Feb 12, 2026 |
| FY2025 | Dec 28, 2024 | $67.00M | Feb 12, 2026 |
| FY2025 | Dec 30, 2023 | $64.70M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $60.10M | Feb 13, 2025 |
| FY2023 | Jan 1, 2022 | $61.10M | Feb 16, 2024 |
| FY2022 | Jan 2, 2021 | $57.40M | Feb 9, 2023 |
| FY2021 | Dec 28, 2019 | $59.10M | Feb 11, 2022 |
| FY2020 | Dec 29, 2018 | $61.20M | Feb 11, 2021 |
| FY2019 | Dec 30, 2017 | $60.90M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $53.40M | Feb 14, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $1.08B | Feb 12, 2026 |
| FY2025 | Dec 28, 2024 | $1.22B | Feb 12, 2026 |
| FY2025 | Dec 30, 2023 | $1.15B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $675.20M | Feb 13, 2025 |
| FY2023 | Jan 1, 2022 | $966.60M | Feb 16, 2024 |
| FY2022 | Jan 2, 2021 | $1.01B | Feb 9, 2023 |
| FY2021 | Dec 28, 2019 | $674.60M | Feb 11, 2022 |
| FY2020 | Dec 29, 2018 | $764.50M | Feb 11, 2021 |
| FY2019 | Dec 30, 2017 | $608.50M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $576.10M | Feb 14, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $8.41B | Feb 12, 2026 |
| FY2025 | Dec 28, 2024 | $7.90B | Feb 12, 2026 |
| FY2024 | Dec 30, 2023 | $7.54B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $6.97B | Feb 16, 2024 |
| FY2022 | Jan 1, 2022 | $6.76B | Feb 9, 2023 |
| FY2021 | Jan 2, 2021 | $6.56B | Feb 11, 2022 |
| FY2020 | Dec 28, 2019 | $5.69B | Feb 11, 2021 |
| FY2019 | Dec 29, 2018 | $5.37B | Feb 13, 2020 |
| FY2018 | Dec 30, 2017 | $5.25B | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $4.72B | Feb 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $2.46B | Feb 12, 2026 |
| FY2025 | Dec 28, 2024 | $2.48B | Feb 12, 2026 |
| FY2024 | Dec 30, 2023 | $2.45B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $2.47B | Feb 16, 2024 |
| FY2022 | Jan 1, 2022 | $2.56B | Feb 9, 2023 |
| FY2021 | Jan 2, 2021 | $2.71B | Feb 11, 2022 |
| FY2020 | Dec 28, 2019 | $2.26B | Feb 11, 2021 |
| FY2019 | Dec 29, 2018 | $2.25B | Feb 13, 2020 |
| FY2018 | Dec 30, 2017 | $2.28B | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $2.09B | Feb 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $5.93B | Feb 12, 2026 |
| FY2025 | Dec 28, 2024 | $5.39B | Feb 12, 2026 |
| FY2024 | Dec 30, 2023 | $5.07B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $4.48B | Feb 16, 2024 |
| FY2022 | Jan 1, 2022 | $4.18B | Feb 9, 2023 |
| FY2021 | Jan 2, 2021 | $3.82B | Feb 11, 2022 |
| FY2020 | Dec 28, 2019 | $3.41B | Feb 11, 2021 |
| FY2019 | Dec 29, 2018 | $3.10B | Feb 13, 2020 |
| FY2018 | Dec 30, 2017 | $2.95B | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $2.62B | Feb 15, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $1.11B | Feb 12, 2026 |
| FY2025 | Dec 28, 2024 | $1.06B | Feb 12, 2026 |
| FY2025 | Dec 30, 2023 | $1.10B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.05B | Feb 13, 2025 |
| FY2023 | Jan 1, 2022 | $1.12B | Feb 16, 2024 |
| FY2022 | Jan 2, 2021 | $982.40M | Feb 9, 2023 |
| FY2021 | Dec 28, 2019 | $913.80M | Feb 11, 2022 |
| FY2020 | Dec 29, 2018 | $902.20M | Feb 11, 2021 |
| FY2019 | Dec 30, 2017 | $924.10M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $895.50M | Feb 14, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $8.14B | Feb 12, 2026 |
| FY2025 | Dec 28, 2024 | $7.58B | Feb 12, 2026 |
| FY2024 | Dec 30, 2023 | $6.95B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $6.30B | Feb 16, 2024 |
| FY2022 | Jan 1, 2022 | $5.70B | Feb 9, 2023 |
| FY2021 | Jan 2, 2021 | $5.16B | Feb 11, 2022 |
| FY2020 | Dec 28, 2019 | $4.78B | Feb 11, 2021 |
| FY2019 | Dec 29, 2018 | $4.26B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $3.77B | Feb 14, 2019 |
| FY2018 | Dec 30, 2017 | $3.77B | Feb 14, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $1.62B | Feb 12, 2026 |
| FY2025 | Dec 28, 2024 | $1.36B | Feb 12, 2026 |
| FY2024 | Dec 30, 2023 | $1.00B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $757.20M | Feb 16, 2024 |
| FY2022 | Jan 1, 2022 | $780.00M | Feb 9, 2023 |
| FY2021 | Jan 2, 2021 | $923.40M | Feb 11, 2022 |
| FY2020 | Dec 28, 2019 | $184.50M | Feb 11, 2021 |
| FY2019 | Dec 29, 2018 | $140.90M | Feb 13, 2020 |
| FY2018 | Dec 30, 2017 | $92.00M | Feb 14, 2019 |
| FY2018 | Dec 31, 2016 | $77.60M | Feb 14, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $1.20B | Feb 12, 2026 |
| FY2025 | Dec 28, 2024 | $1.20B | Feb 12, 2026 |
| FY2015 | Jan 2, 2016 | $880.10M | Feb 11, 2016 |
| FY2015 | Jan 3, 2015 | $919.30M | Feb 11, 2016 |
| FY2014 | Dec 28, 2013 | $972.00M | Feb 12, 2015 |
| FY2013 | Dec 29, 2012 | $975.60M | Feb 14, 2014 |
| FY2012 | Dec 31, 2011 | $984.10M | Feb 14, 2013 |
| FY2011 | Jan 1, 2011 | $1.17B | Feb 16, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | 19 | Feb 12, 2026 |
| FY2025 | Dec 28, 2024 | 19 | Feb 12, 2026 |
| FY2025 | Dec 30, 2023 | 19 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 17 | Feb 13, 2025 |
| FY2023 | Jan 1, 2022 | 15 | Feb 16, 2024 |
| FY2020 | Jan 2, 2021 | 3 | Feb 11, 2021 |
| FY2020 | Sep 26, 2020 | 3 | Feb 11, 2021 |
| FY2020 | Jun 27, 2020 | 1 | Feb 11, 2021 |
| FY2020 | Mar 28, 2020 | 2 | Feb 11, 2021 |
| FY2020 | Dec 28, 2019 | 3 | Feb 11, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | 19 | Feb 12, 2026 |
| FY2025 | Dec 28, 2024 | 19 | Feb 12, 2026 |
| FY2025 | Dec 30, 2023 | 18 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 16 | Feb 13, 2025 |
| FY2023 | Jan 1, 2022 | 14 | Feb 16, 2024 |
| FY2020 | Jan 2, 2021 | 3 | Feb 11, 2021 |
| FY2020 | Sep 26, 2020 | 3 | Feb 11, 2021 |
| FY2020 | Jun 27, 2020 | 1 | Feb 11, 2021 |
| FY2020 | Mar 28, 2020 | 2 | Feb 11, 2021 |
| FY2020 | Dec 28, 2019 | 3 | Feb 11, 2021 |